Retatrutide
Late-stage investigational triple agonist
Brief Overview: Retatrutide activates GLP-1, GIP, and glucagon receptors. The glucagon component is the key differentiator from tirzepatide and may contribute to greater energy-expenditure and liver-fat effects, but it may also change tolerability. Evidence lens: The evidence is strong for an investigational compound but not the same as an approved product. Phase 2 results are impressive, while Phase 3 and final labeling determine the real risk-benefit profile. How to read this: if you're new, don't treat gray-market retatrutide as equivalent to clinical-trial retatrutide. Once you're past the basics, compare trial dose, titration speed, GI events, heart rate, dysesthesia, gallbladder/pancreatic signals, and lean-mass preservation.
- Developed by Eli Lilly under the code LY3437943, retatrutide is a single synthetic peptide (not a combination of drugs), engineered so one molecule activates three receptors at once.
- First-in-class “triple G” agonist: it targets the GLP-1, GIP, and glucagon receptors together, and is the first such tri-agonist to reach Phase 3 development.
- Long-acting by design: an albumin-binding fatty-acid chain extends its half-life to about six days, supporting once-weekly subcutaneous dosing (see Section 5).
- Class & status: an investigational incretin/glucagon receptor agonist (metabolic). It is not an FDA-approved drug as of this edition and has no approved label.
- Studied for obesity, obesity with knee osteoarthritis (TRIUMPH program), type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD).
- Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. It is distinct from semaglutide and tirzepatide rather than simply a stronger GLP-1.
One molecule, three receptor “arms,” all class B, G s -coupled GPCRs that signal through cAMP:
- GLP-1 receptor: glucose-dependent insulin release, hypothalamic satiety, and slowed gastric emptying, the appetite-and-intake arm shared with semaglutide.
- GIP receptor: adds a β-cell insulin response and adipose nutrient handling, and is thought to help blunt the nausea of GLP-1 activation, the same arm tirzepatide adds.
- Glucagon receptor, the differentiator: raises energy expenditure and drives hepatic fat oxidation/lipolysis, which underlies both the larger weight loss and the marked liver-fat reduction not seen with dual agonists.
- The balancing act: glucagon on its own would raise hepatic glucose output, so the GLP-1/GIP insulin arms must offset it; In trials net glucose control still improved. The glucagon arm also helps explain the dose-dependent rise in heart rate (Section 7).
- Its profile combines incretin satiety/glucose effects with glucagon-receptor activity that may increase energy expenditure and hepatic/metabolic effects. That broader mechanism may also broaden tolerability and monitoring issues. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Two Phase 3 trials in the TRIUMPH program have now reported positive topline results: TRIUMPH-4 (Dec 2025, obesity plus knee osteoarthritis) reported about 28.7% mean weight loss at 68 weeks at the 12 mg dose, and TRIUMPH-1 (May 2026, obesity/overweight with at least one weight-related comorbidity) reported about 28.3% at 80 weeks at 12 mg, with continued loss in a higher-BMI extension.
- Earlier Phase 2 data had shown substantial weight-loss signals.
- Positive topline readouts are not the same as full peer-reviewed publication or regulatory approval, and additional TRIUMPH and TRANSCEND readouts plus dedicated cardiovascular-outcomes data remain pending; Long-term safety is not yet established.
- Large trial programs have produced strong weight-loss signals, but full peer-reviewed data and final regulatory labeling matter. Sponsor topline language stays topline until published/adjudicated. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: TRIUMPH-4 Protocol (12 mg target) [Clinical/Human Trial]; Route: Subcutaneous, abdomen preferred; Dose: Starting dose: 2 mg weekly (weeks 1–4); Frequency: Once weekly; Duration: Trial escalation/maintenance; Max: 12 mg weekly; Titration/loading: Step up every 4 weeks on a fixed schedule; Typical step size 2–3 mg (2, 4, 6, 9, 12); Scheduled escalation regardless of response.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Community Slow Titration [Community/Biohacker/Anecdotal]; Route: Subcutaneous, abdomen preferred; Dose: Starting dose: 0.5 mg – 1 mg weekly; Frequency: Once weekly; Max: 12 mg weekly, only if truly needed; Titration/loading: Hold current dose unless weight loss has stalled or cravings/appetite returned; Typical step size 0.5 – 1 mg; Escalate only when plateaued.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Community dose-hold/reduction and missed-dose rules [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: No fixed dose; Applies to any current retatrutide dose during slow titration.; Frequency: Once weekly SC dosing context; Timing: If tolerability issues occur at a dose step, hold that dose longer or reduce to the prior tolerated dose.; Duration: Hold current dose an additional 1-4 weeks before retrying escalation, or step back to prior tolerated dose.; Max: 12 mg weekly ceiling in guide/trial context; Community slow titration typically seeks lowest effective dose.; Titration/loading: Dose changes are not fully felt for roughly 3-4 weeks because of ~6-day half-life and steady-state drift.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Dosing is trial- and product-specific, with titration. Do not import tirzepatide or semaglutide schedules into research-market retatrutide. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: about 30 days, or roughly 4-5 weeks.
- Half-life basis: Approximately 6 days in phase 2 obesity literature. This supports once-weekly dosing in trials; Final prescribing information will control after approval.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- Practical interpretation: Retatrutide is designed for weekly dosing, but final label pharmacokinetics and dose escalation come from the approved label if approval occurs.
- Long-acting weekly design is expected, but clinical titration is driven by tolerability and metabolic response rather than half-life alone. GI effects may lag dose changes. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- It is already a “stack in one molecule”: three receptor arms are combined by design, so adding another incretin or amylin drug is redundant receptor pressure, not synergy, the same-pathway problem this guide flags elsewhere (the Stacking Calculator scores incretin + incretin as a penalty).
- Do not combine with semaglutide, tirzepatide, liraglutide, CagriSema, cagrilintide, or other GLP-1/GIP/amylin agents outside a trial: expect additive GI distress, gallbladder disease, dehydration/AKI, and hypoglycemia.
- With insulin or sulfonylureas the hypoglycemia risk is greatest; In diabetes these combinations typically require lowering the insulin/sulfonylurea dose under medical supervision.
- Supportive care is not a stack: hydration and anti-nausea measures during titration address tolerability, and they are not efficacy or “performance” stacking.
- Stacking with other GLP-1/GIP/amylin agents calls for high caution because mechanisms overlap. Combining with insulin/secretagogues or appetite suppressants increases safety complexity. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
Gastrointestinal (expected, dose-dependent).
- At the 12 mg dose in TRIUMPH-4: nausea 43.2%, diarrhea 33.1%, constipation 25.0%, vomiting 20.9%, decreased appetite 18.2%.
- At 9 mg: nausea 38.1%, diarrhea 34.7%, constipation 21.8%, vomiting 20.4%.
- Placebo nausea: 10.7%. Most events were mild to moderate, clustered around each dose step, and improved at stable maintenance. Roughly 18.2% of 12 mg patients discontinued for adverse events; Lilly’s topline TRIUMPH-4 disclosure states that some discontinuations due to adverse events included “perceived excessive weight loss”; Treat this as sponsor-reported topline wording, not a fully published discontinuation taxonomy until full trial data are available. The slow-titration approach described in Section 4 is designed specifically to keep patients below the dose range where these rates emerge. Dysesthesia (Phase 3 signal, but not unique to retatrutide, a known GLP-1 class effect; The high-dose 7.2 mg semaglutide label reports ~22%). Abnormal skin sensations (tingling, burning, prickling, altered touch) reported in 20.9% of 12 mg patients and 8.8% of 9 mg patients, vs 0.7% on placebo. Phase 2 had shown a smaller signal (~7%). Events were mild, rarely led to discontinuation, did not always localize to the injection site, and most resolved during the trial. Mechanism unknown; Leading hypotheses involve glucagon-receptor activation on peripheral nerves or rapid metabolic shifts producing small-fiber neuropathic symptoms. This is not seen with semaglutide or tirzepatide and is currently the most distinctive non-GI finding of the TRIUMPH program. Heart rate. Dose-dependent increase of 5 to 10 bpm, peaking around week 24. Cardiac arrhythmias in 2 to 11% of retatrutide participants vs 2% placebo; None classified as serious. No MACE increase reported; Dedicated cardiovascular-outcomes data (TRIUMPH-3) not yet available. Liver enzymes. Transient ALT/AST elevations greater than 3 times ULN in approximately 1% of Phase 2 participants, usually tied to dose escalation. Mean ALT decreased or stayed stable at 48 weeks; A Phase 2a MASLD sub-analysis showed 86% of 12 mg participants achieved normal liver fat by 24 weeks.
- Serious class-level risks: pancreatitis (rare, class effect), gallbladder disease (gallstones, cholecystitis; Rapid weight loss raises baseline risk), acute kidney injury from dehydration secondary to GI losses, and diabetic retinopathy worsening (reported with semaglutide; Not yet characterized for retatrutide).
- Boxed-warning class concern: thyroid C-cell tumors in rodent studies apply to the entire GLP-1 class. Retatrutide has no FDA label yet, so the following are expected class cautions / trial-exclusion criteria rather than established contraindications: personal or family history of Medullary Thyroid Carcinoma (MTC) or MEN 2.
- Expected cautions (GLP-1 class / trial exclusions): personal or family history of MTC or MEN 2; Prior pancreatitis; Active gallbladder disease; Pregnancy, breastfeeding, or active attempts to conceive; Severe renal impairment (insufficient data); Severe hepatic impairment (insufficient data).
- Expected concerns include GI adverse effects, dehydration, gallbladder disease, pancreatitis signals, heart-rate changes, glucose effects, and excessive weight loss. Glucagon activity makes liver/metabolic context important. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
A pragmatic baseline-and-escalation panel:
- Baseline (before first dose): CBC, CMP, HbA1c, fasting glucose, fasting insulin, lipid panel, TSH with free T4, amylase, lipase, ALT, AST, GGT, creatinine, eGFR, Cystatin C (more sensitive than creatinine during rapid weight loss), pregnancy test where applicable.
- At each dose change (slow titration): ALT/AST, creatinine, amylase/lipase. Catches early liver stress, dehydration-driven AKI, or pancreatic irritation before it becomes symptomatic.
- At stable maintenance (every 8 to 12 weeks): full repeat panel.
- Efficacy tracking: body weight and waist circumference (waist-to-height ratio captures visceral loss better than scale weight); Body composition by DEXA every 3 to 6 months to distinguish fat loss from sarcopenia; HbA1c (expect 1.3% to 2.0% reduction in diabetic subjects); Blood pressure (expect ~14 mmHg systolic reduction at 12 mg; Smaller at lower doses); Liver enzymes (expect improvement in ALT over 24 weeks if MASLD at baseline); Resting heart rate (track 5 to 10 bpm increase; Flag if greater than 15 bpm sustained).
- Safety tracking: pancreatic enzymes at baseline and if symptomatic; Gallbladder ultrasound if right-upper-quadrant pain develops; Neurological check at each visit for dysesthesia (document distribution, severity, whether progressive); Mental-health screen (rapid weight loss changes body image and may destabilize eating-disorder history).
- Track weight-loss rate, GI tolerance, hydration, glucose/A1c, lipids, liver enzymes, gallbladder symptoms, pulse, blood pressure, and nutrition/protein intake. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Investigational in the current reference context. With TRIUMPH-1 and TRIUMPH-4 positive, an NDA filing is anticipated around late 2026 or 2027, contingent on the remaining pivotal readouts.
- Projected approval timeline: 2027, likely initially for obesity with comorbidities.
- GlobalData analyst projections: $15.6B peak annual sales by 2031.
- Anti-doping: while investigational and not approved as a therapeutic product, retatrutide can create S0 non-approved-substance risk for athletes. Do not claim it will automatically be S2-prohibited upon approval; GLP-1 agents have been monitored by WADA but are not automatically prohibited. If retatrutide is later approved, verify current status through WADA/Global DRO/USADA rather than assuming a class ban.
- Availability (April 2026): Clinical-trial settings only. No legal, FDA-approved commercial source. Gray-market “research chemical” vendors do offer retatrutide, but quality analyses have found significant purity and potency variability. For athletes, investigational retatrutide is high-risk under WADA S0 (non-approved pharmacological substance); If it is later approved, verify anti-doping status directly through WADA, USADA, or Global DRO. Gray-market warning Unapproved retatrutide products can involve mislabeling, incorrect dose, wrong molecule, contamination, or counterfeit supply. FDA enforcement letters and safety warnings around compounded or counterfeit incretin products are relevant cautionary context.
- Retatrutide is investigational and not FDA-approved. Research-market products are not equivalent to trial material or future approved labeling. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.